Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients With Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

NCT04978727 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT04978727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04978727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients With Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Lead sponsor
Children's Oncology Group
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 1, 2022
Completion date
December 31, 2027
Enrollment
35 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligodendroglioma, diffuse intrinsic pontine glioma, ependymoma, glioblastoma multiforme, high-grade astrocytoma nos, medulloblastoma